Date: 2014-01-13
Type of information: R&D agreement
Compound:
Company: Argen-X (The Netherlands-Belgium) Boehringer Ingelheim (Germany)
Therapeutic area: undisclosed
Type agreement: R&D
Action mechanism:
Disease:
Details: * On January 13, 2014, arGEN-X has announced the initiation of a new pilot research agreement with Boehringer Ingelheim. No further details are being disclosed at this stage.
Financial terms:
Latest news:
